Navigation Links
FDA Sets Action Date of April 23, 2010 for Review of Pixantrone NDA
Date:9/5/2009

p>

About Fast Track

Fast track is a process designed to facilitate the development, and expedite the review of drugs to treat serious diseases and fill an unmet medical need. Filling an unmet medical need is defined as providing a therapy where none exists or providing a therapy which may be potentially superior to existing therapy.

About Cell Therapeutics, Inc.

Headquartered in Seattle, CTI is a biopharmaceutical company committed to developing an integrated portfolio of oncology products aimed at making cancer more treatable. For additional information, please visit www.CellTherapeutics.com.

Sign up for email alerts and get RSS feeds at our Web site,http://www.CellTherapeutics.com/investors_news.htm

This press release includes forward-looking statements that involve a number of risks and uncertainties, the outcome of which could materially and/or adversely affect actual future results and the trading price of our securities. Specifically, the risks and uncertainties that could affect the development of pixantrone include risks associated with preclinical and clinical developments in the biopharmaceutical industry in general, and with pixantrone in particular, including, without limitation, the potential failure of pixantrone to prove safe and effective for the treatment of relapsed or refractory aggressive NHL as determined by the FDA, and that a decision by the FDA is not rendered by April 23, 2010, and that pixantrone may not be available to patients in the second quarter of 2010, the possibility that the follow-up data does not demonstrate continued improvement in the primary and secondary endpoints, CTI's ability to continue to raise capital as needed to fun
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Real-World Study Showed Cost Savings for VTE Prophylaxis with Enoxaparin Compared with Unfractionated Heparin (UFH)
2. Mars, Incorporated Commits Over $2 Million to Federal Agency for Human-Animal Interaction Research
3. Shire Reports Positive Results From First of Three Phase III Trials of velaglucerase alfa for Type 1 Gaucher Disease and Provides Important Updates on Interactions With FDA
4. Novel Valortim(R) Mechanism of Action Data Presented at the Keystone Symposia on Molecular and Cellular Biology
5. Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP
6. ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer
7. Nebulized Perforomist(TM) Inhalation Solution Provided Prolonged Bronchodilation and Increased Patient Satisfaction Compared to Albuterol/Ipratropium MDI
8. APTA Supports Surgeon Generals Call to Action to Prevent Deep Vein Thrombosis and Pulmonary Embolism
9. Surgeon Generals Call to Action to Prevent DVT/PE Praised by NATT as Turning Point
10. U.S. FDA Issues Action Letter for Sugammadex
11. Medivation Presents Positive New Data on Dimebons Long-Term Efficacy and Novel Mechanism of Action at the International Conference on Alzheimers Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2014)... DIEGO , Nov. 24, 2014  GlySens Incorporated ... two million dollar grant from the National Institute of ... of the National Institutes of Health (NIH).  The grant ... GlySens second generation ICGM™ long term implantable glucose monitoring ... underway, and enrollment is expected to begin before the ...
(Date:11/23/2014)... HAYWARD, Calif. , Nov. 23, 2014 ... today that Paul F. Truex , President and ... the 2014 Annual Piper Jaffray Healthcare Conference. ... rd , at the Palace Hotel in ... Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmaceutical ...
(Date:11/22/2014)... de 2014  BioClinica®, Inc., un proveedor líder ... eClinical, ha indicado un aumento de la demanda ... seguimiento basado en el riesgo en los ensayos ... seguimiento basado en el riesgo más allá de ... o cambio de los métodos de seguimiento. Se ...
Breaking Medicine Technology:GlySens Incorporated Awarded $2 Million Grant from the National Institutes of Health 2Anthera Pharmaceuticals to Present at Annual Piper Jaffray Healthcare Conference 2El 'seguimiento inteligente' consigue un excelente momento 2El 'seguimiento inteligente' consigue un excelente momento 3
... PLC ), a company focused on innovative cardiac ... the three,and twelve month periods ended December 31, 2007., ... with,$1,747,000 in the fourth quarter of 2006. The net ... $0.03 per diluted share, compared to net,income of $36,000, ...
... XYOTAX to be reviewed for PS2 first-line non-small cell lung cancer ... ... March 4 Cell Therapeutics, Inc.,(CTI) (Nasdaq and MTA: CTIC) announced ... Medicines Agency (EMEA) for,XYOTAX(TM) (paclitaxel poliglumex, CT-2103) for first-line treatment of,patients ...
Cached Medicine Technology:PLC Systems Reports Fourth Quarter 2007 Results 2PLC Systems Reports Fourth Quarter 2007 Results 3PLC Systems Reports Fourth Quarter 2007 Results 4PLC Systems Reports Fourth Quarter 2007 Results 5PLC Systems Reports Fourth Quarter 2007 Results 6Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 2Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 3Cell Therapeutics, Inc. (CTI) Submits European Marketing Authorization Application for XYOTAX(TM) 4
(Date:11/24/2014)... (PRWEB) November 24, 2014 Olaparib functions ... polymerase (PARP) and is one of the first PARP ... to creating some types of melanoma, and are often ... also sometimes gives their malignancies a exclusive weaknesses, as ... to fix their DNA and allow them to proceed ...
(Date:11/24/2014)... The Holiday Inn Westbury - Long ... Children's Association to donate various items consisting of ... other such items.The Association's program is aimed toward helping ... in nursing homes, assisted living facilities and nursing homes. ... being of seniors throughout the Long Island area. The ...
(Date:11/24/2014)... Raymond, Alberta (PRWEB) November 24, 2014 ... of people each day. They break up families, ... there is new hope for those that suffer,” ... “Ground-breaking scientific research is showing that our specialized ... , Hardy will appear on “Mind Over Matter”, ...
(Date:11/24/2014)... SafeHandles™ announced that they will be featured in ... airing via Discovery Channel. Dates and show times TBA. ... replaceable, and affordable germ protective device. This segment will ... adhesives to promote hand hygiene in high traffic and ... is the desire to make a positive impact in ...
(Date:11/24/2014)... Gersowitz Libo & Korek, P.C., a leading ... Tier recognition in the 2015 Edition of U.S. News-Best Lawyers ... a unique combination of quality law practice and breadth of ... honor and especially grateful to our clients whose continued support ... possible,” said Jeff S. Korek, senior partner at Gersowitz ...
Breaking Medicine News(10 mins):Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 2Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 3Health News:Olaparib Industry (CAS 763113-22-0) 2009-2019 Global and China Research Reports is Now Available at RnRMarketResearch.com 4Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 2Health News:Nutritional Mental Health Treatment Featured on Access Health Airing on Lifetime Television® 3Health News:New Episode of Innovations TV Series to Feature SafeHandles™ 2Health News:U.S. News-Best Lawyers “Best Law Firms” Names Gersowitz Libo & Korek P.C. a 2015 Tier 1 Ranking Firm 2
... Sept. 21 Roper Industries,Inc. (NYSE: ROP ) ... 2007, ended September 30, 2007, will be released after ... call to discuss these results,has been scheduled for 10:00 ... be accessed via webcast or by dialing +1 888-801-6506 ...
... SAN DIEGO, Sept. 21 ChemDiv, Inc. (San ... (CDRI, Moscow) is,undertaking a partnership with the Blokhin ... Medical Sciences, the US Department of Energy,(DOE), and ... novel small,molecule therapies for the prevention and treatment ...
... On Sept. 18, the,Michigan Association of Health Plans ... award reception at which eight Michigan HMOs received,the ... as these,are leading the way in serving participants ... "Michigan needs more,health care plans that expand outreach, ...
... are at high risk for preterm birth, giving them a ... babys chances of having serious lung problems after birth. , ... new study shows that repeat courses of corticosteroids are linked ... these mothers. , Our study shows that you get almost ...
... of studies shows big survival gains , THURSDAY, ... regimens of irinotecan, oxaliplatin, and molecular-targeted treatments are ... months longer than they did a few years ... say. , Researchers at the University of Ioannina ...
... 18, 2007 -- Recently, researchers at Iowa State University ... popular crop model. By zeroing in on early stages ... help improve yield predictions across a variety of environmental ... the September-October issue of Crop Science. , The Crop ...
Cached Medicine News:Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 2Health News:Chemical Diversity Initiates International Prostrate Cancer Discovery Partnership 3Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 2Health News:Eight Michigan HMOs, Two Providers, Take Top Honors for Quality Health Care 3Health News:Multiple corticosteroid injections in pregnant women may increase cerebral palsy 2Health News:Experts Compare Colon Cancer Treatment Outcomes 2Health News:Simulating kernel production influences maize model accuracy 2
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
Khosla Precision and Quality in Medical and Surgical Products....
... For Anterior and Posterior segment surgeries ... using Ventury or Peristaltic Linear Aspiration. ... for specific cutting action. Easy to ... movement. Cutting speed-variable from 1- 600 ...
Medicine Products: